A bipartisan bill brought forward in the U.S. House of Representatives April 4 would coordinate an international initiative for the prevention and treatment of Alzheimer’s disease and other dementias.

GE Healthcare announced yesterday that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the company’s PET/CT iterative image reconstruction technology that works to improve image quality and quantitative data.

Shine Medical Technologies based in Monona, Wis., has solidified a deal with GE Healthcare to provide consistent production of molybdenum-99, which decays into technetium-99m—the medical isotope most used throughout the world in nuclear medicine procedures, the company announced last week.

Drug policy in the European Union could change in the not too distant future depending on a vote regarding a law proposed to discourage pharmaceutical companies from playing favorites when it comes to clinical trials.

While the prostate naturally relies on lipid metabolism, there is a way to reroute metabolic function and activate glucose uptake, which provides a novel means of FDG and other metabolic prostate imaging, according to a study presented during the American Association for Cancer Research (AACR) annual meeting being held April 5-9 in San Diego, Calif.

Strand Genomics, the genomics software company in Rockville, Md., and San Francisco, Calif., announced April 1 that a selection of technology has been prepared for the company’s Strand Centers for Genomics and Personalized Medicine across the U.S.

A neural stem cell treatment is stepping up in the hopes of one day helping stroke patients regain more neurologic function.

Not only does alcoholism lead to neural atrophy and diminish total brain weight, but it also leads to a dramatic drop in the levels of select proteins in the brain, according to an article published April 3 in PLOS ONE.